Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.64%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.36 per share when it actually produced a loss of $0.53, delivering a surprise of -47.22%.Over the last four quarters ...

Core Viewpoint - Ares Management reported quarterly earnings of $1.09 per share, exceeding the Zacks Consensus Estimate of $0.94 per share, and showing an increase from $0.80 per share a year ago, indicating a 15.96% earnings surprise [1] Group 1: Earnings Performance - The company surpassed consensus EPS estimates three times over the last four quarters [2] - Ares Management's revenues for the quarter ended March 2025 were $897.58 million, missing the Zacks Consensus Estimate by 1.76%, compared to $736.42 million in the same quarter last year [2] - The company has topped consensus revenue estimates only once in the last four quarters [2] Group 2: Stock Performance and Outlook - Ares Management shares have declined approximately 11.3% since the beginning of the year, while the S&P 500 has decreased by 3.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.19 on revenues of $1.15 billion, and for the current fiscal year, it is $4.93 on revenues of $4.79 billion [7] Group 3: Industry Context - The Financial - Investment Management industry, to which Ares Management belongs, is currently ranked in the bottom 13% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ares Management's stock performance [5]

Telephone & Data Systems (TDS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -350%. A quarter ago, it was expected that this parent of U.S. Cellular and TDS Telecom would post a loss of $0.32 per share when it actually produced a loss of $0.09, delivering a surprise of 71.88%.Over the l ...

Financial Performance - Butterfly Network, Inc. reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.07 per share a year ago, indicating an earnings surprise of 33.33% [1] - The company posted revenues of $21.23 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.58%, but showing an increase from year-ago revenues of $17.66 million [2] - Over the last four quarters, Butterfly Network has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Butterfly Network shares have declined approximately 25% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The company's current Zacks Rank is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $24.46 million, and for the current fiscal year, it is -$0.32 on revenues of $97.54 million [7] - The trend of estimate revisions for Butterfly Network is currently favorable, which could influence future stock movements [5][6] Industry Context - The Medical Info Systems industry, to which Butterfly Network belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Group 1: Earnings Performance - Cigna reported quarterly earnings of $6.74 per share, exceeding the Zacks Consensus Estimate of $6.39 per share, and showing an increase from $6.47 per share a year ago, representing an earnings surprise of 5.48% [1] - The company posted revenues of $65.45 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.66%, compared to year-ago revenues of $57.25 billion [2] - Over the last four quarters, Cigna has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Cigna shares have increased approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $7.17 on revenues of $61.56 billion, and for the current fiscal year, it is $29.61 on revenues of $252.36 billion [7] Group 3: Industry Context - The Medical - HMOs industry, to which Cigna belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cigna's stock performance [5] - The Zacks Rank for Cigna is currently 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Company Performance - Select Medical reported quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share, and down from $0.77 per share a year ago, representing an earnings surprise of -2.22% [1] - The company posted revenues of $1.35 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.83%, and down from $1.79 billion year-over-year [2] - Over the last four quarters, Select Medical has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Select Medical shares have lost about 3.2% since the beginning of the year, compared to the S&P 500's decline of -5.3% [3] - The current consensus EPS estimate for the coming quarter is $0.25 on revenues of $1.33 billion, and for the current fiscal year, it is $1.14 on revenues of $5.39 billion [7] Industry Outlook - The Medical - HMOs industry, to which Select Medical belongs, is currently in the top 15% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Select Medical's stock performance [5][6]

Group 1: Earnings Performance - American International Group (AIG) reported quarterly earnings of $1.17 per share, exceeding the Zacks Consensus Estimate of $1.05 per share, but down from $1.77 per share a year ago, representing an earnings surprise of 11.43% [1] - The company posted revenues of $6.62 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.59%, and down from $12.47 billion year-over-year [2] - Over the last four quarters, AIG has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2: Stock Performance and Outlook - AIG shares have increased approximately 12% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] - The future performance of AIG's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is $1.69 on revenues of $6.99 billion, and for the current fiscal year, it is $6.15 on revenues of $27.84 billion [7] Group 3: Industry Context - The Zacks Industry Rank indicates that the Insurance - Multi line sector is currently in the top 20% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AIG's stock performance [5]

Core Insights - Pro-Dex, Inc. (PDEX) reported quarterly earnings of $0.98 per share, significantly exceeding the Zacks Consensus Estimate of $0.47 per share, and up from $0.19 per share a year ago, representing an earnings surprise of 108.51% [1] - The company posted revenues of $17.41 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 1.62%, but up from $14.29 million year-over-year [2] - Pro-Dex shares have increased approximately 40.5% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $18.5 million, and for the current fiscal year, it is $2.30 on revenues of $67.9 million [7] - The estimate revisions trend for Pro-Dex is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which Pro-Dex belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Dentsply International (XRAY), is expected to report a year-over-year earnings decline of 31% for the quarter ended March 2025, with revenues anticipated to drop by 10.7% [9][10]

Core Viewpoint - Lumen reported a quarterly loss of $0.13 per share, which was better than the Zacks Consensus Estimate of a loss of $0.29, indicating a significant earnings surprise of 55.17% [1] Financial Performance - The company posted revenues of $3.18 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.71%, although this represents a decline from $3.29 billion in the same quarter last year [2] - Over the last four quarters, Lumen has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - Lumen shares have declined approximately 33.3% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The current Zacks Rank for Lumen is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $3.08 billion, and for the current fiscal year, it is -$1.11 on revenues of $12.39 billion [7] - The trend of estimate revisions for Lumen is mixed, which could change following the recent earnings report [6] Industry Context - The Diversified Communication Services industry, to which Lumen belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Telus, another company in the same industry, is expected to report quarterly earnings of $0.15 per share, reflecting a year-over-year decline of 21.1% [9]

United States Steel (X) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to earnings of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.75%. A quarter ago, it was expected that this steel maker would post a loss of $0.25 per share when it actually produced a loss of $0.13, delivering a surprise of 48%.Over the last four quarters, the company has su ...